-
公开(公告)号：US11419955B2
公开(公告)日：2022-08-23
申请号：US16714182
申请日：2019-12-13
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , G01N33/574 , G01N33/543 , G01N33/552 , G01N33/58 , G01N33/60 , A61K49/00
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US20200376149A1
公开(公告)日：2020-12-03
申请号：US16714182
申请日：2019-12-13
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , G01N33/574 , G01N33/543 , G01N33/552 , G01N33/58 , G01N33/60 , A61K49/00
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US20180326103A1
公开(公告)日：2018-11-15
申请号：US16009267
申请日：2018-06-15
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , A61K49/00 , G01N33/574 , G01N33/543 , G01N33/58 , G01N33/552 , G01N33/60
CPC分类号： A61K51/1244 , A61K49/0002 , A61K49/0093 , G01N33/54346 , G01N33/552 , G01N33/574 , G01N33/582 , G01N33/587 , G01N33/60
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US09999694B2
公开(公告)日：2018-06-19
申请号：US14215879
申请日：2014-03-17
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , G01N33/574 , G01N33/543 , G01N33/552 , G01N33/58 , G01N33/60 , A61K49/00
CPC分类号： A61K51/1244 , A61K49/0002 , A61K49/0093 , G01N33/54346 , G01N33/552 , G01N33/574 , G01N33/582 , G01N33/587 , G01N33/60
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US10039847B2
公开(公告)日：2018-08-07
申请号：US15714189
申请日：2017-09-25
申请人： Sloan-Kettering Institute for Cancer Research , Cornell University , The Curators of the University of Missouri
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson , Thomas P. Quinn
IPC分类号： A61K51/12 , A61K49/00 , G01N33/574 , G01N33/60 , G01N33/58 , G01N33/552 , G01N33/543
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US20140248210A1
公开(公告)日：2014-09-04
申请号：US14215879
申请日：2014-03-17
发明人： Michelle Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason Lewis , Steven Larson , Tom Quinn
CPC分类号： A61K51/1244 , A61K49/0002 , A61K49/0093 , G01N33/54346 , G01N33/552 , G01N33/574 , G01N33/582 , G01N33/587 , G01N33/60
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
摘要翻译： 本发明提供一种允许精确检测，表征，监测和治疗诸如癌症的疾病的荧光二氧化硅基纳米颗粒。 纳米颗粒的直径范围包括约0.1nm至约100nm，约0.5nm至约50nm，约1nm至约25nm，约1nm至约15nm，或约1nm至约15nm， 约8nm。 纳米颗粒具有位于纳米颗粒内的荧光化合物，并且具有比游离荧光化合物更大的亮度和荧光量子产率。 纳米颗粒还具有高生物稳定性和生物相容性。 为了促进纳米颗粒的有效尿排泄，可以用有机聚合物如聚（乙二醇）（PEG）包被。 纳米颗粒的小尺寸，二氧化硅基底和有机聚合物涂层在体内施用时使纳米颗粒的毒性最小化。 为了靶向特定的细胞类型，纳米颗粒可进一步与配体结合，该配体能够结合与特定细胞类型相关的细胞成分，例如肿瘤标志物。 在一个实施方案中，治疗剂可以连接到纳米颗粒。 为了允许纳米颗粒不仅可以通过光学荧光成像检测，还可以通过其他成像技术，如正电子发射断层扫描（PET），单光子发射计算机断层扫描（SPECT），计算机断层摄影（CT），生物发光成像和磁共振 成像（MRI），放射性核素/放射性金属或顺磁离子可以与纳米颗粒结合。
-
公开(公告)号：US10548998B2
公开(公告)日：2020-02-04
申请号：US16009267
申请日：2018-06-15
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , G01N33/574 , G01N33/543 , G01N33/552 , G01N33/58 , G01N33/60 , A61K49/00
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US10548997B2
公开(公告)日：2020-02-04
申请号：US15446319
申请日：2017-03-01
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Hooisweng Ow , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , A61K49/00 , A61K51/08 , B82Y5/00 , B82Y15/00 , G01N33/543 , G01N33/58 , A61K9/51 , G01N33/552 , G01N33/574 , G01N33/60
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US20170239378A1
公开(公告)日：2017-08-24
申请号：US15446319
申请日：2017-03-01
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Hooisweng Ow , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , A61K49/00 , A61K9/51 , B82Y15/00 , G01N33/543 , G01N33/552 , G01N33/60 , G01N33/574 , A61K51/08 , G01N33/58
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MM), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
公开(公告)号：US20230158180A1
公开(公告)日：2023-05-25
申请号：US17857413
申请日：2022-07-05
发明人： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC分类号： A61K51/12 , G01N33/574 , G01N33/543 , G01N33/552 , G01N33/58 , G01N33/60 , A61K49/00
CPC分类号： A61K51/1244 , G01N33/574 , G01N33/54346 , G01N33/552 , G01N33/582 , G01N33/587 , G01N33/60 , A61K49/0093 , A61K49/0002
摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.032 秒)
